AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00504530
Drug: Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
DrugBank: Emfilermin (DB06562)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01167244
Drug: BMS-690514
RxNorm normalized name: BMS-690514
DrugBank: BMS-690514 (DB11665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Trial: NCT01324401
Drug: Peanut flour OIT
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
Trial: NCT04582981
Drug: Fruquintinib and raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
Trial: NCT01122121
Drug: Leuprorelin SR
RxNorm normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin SR injection
Trial: NCT01122121
Drug: Flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide tablets
Trial: NCT01708902
Drug: linagliptin2.5mg/metformin1000mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: linagliptin2.5mg/metformin1000mg BID
Trial: NCT01708902
Drug: linagliptin 5mg
RxNorm normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin 5mg once daily
Trial: NCT01708902
Drug: Metformin 500mg
RxNorm normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg BID
Trial: NCT01708902
Drug: linagliptin2.5mg/metformin500mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: linagliptin2.5mg/metformin500mg BID
Trial: NCT01708902
Drug: Metformin 1000mg
RxNorm normalized name: METFORMIN 1000MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1000mg BID
Trial: NCT01890252
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution of 5% NaCl
Trial: NCT04582981
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5mg qd monotherapy
Trial: NCT01810237
Drug: Dabigatran.
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran will be used instead of LMWH for anticoagulation bridging.
Trial: NCT00614705
Drug: PH-797804
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg dose in oral capsule form, once daily for 28 days
Trial: NCT00499590
Drug: bevasiranib
RxNorm normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
Trial: NCT00499590
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
Trial: NCT02624986
Drug: Idasanutlin
RxNorm normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
Trial: NCT02624986
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
Trial: NCT04454437
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT02753140
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02753140
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02753140
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02273726
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa will be administered per dose and schedule specified in the arm.
Trial: NCT02273726
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat will be administered per dose and schedule specified in the arm.
Trial: NCT04448756
Drug: M5049
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
Trial: NCT04448756
Drug: M5049
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received M5049 100 mg orally twice daily for 14 days.
Trial: NCT00184977
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00184977
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01479829
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
Trial: NCT02877927
Drug: Omadacycline
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: po tablets
Trial: NCT02877927
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: po tablets
Trial: NCT02624986
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received a fixed dose of rituximab, 375 mg/m\^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m\^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Trial: NCT04541771
Drug: Lactobacillus Reuteri DSM 17938
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
Trial: NCT00357279
Drug: denufosol tetrasodium (INS37217) Inhalation Solution
DrugBank: Denufosol (DB04983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
Trial: NCT00357279
Drug: Placebo - 0.9% w/v sodium chloride solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
Trial: NCT00442364
Drug: Polidocanol (1%) Microfoam (Varisolve)
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
Trial: NCT03386630
Drug: Hyperbaric bupivacaine+Sufentanil
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
Trial: NCT02152956
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral inhibitor of JAK kinase
Trial: NCT03386630
Drug: Hyperbaric bupivacaine+Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
Trial: NCT00530816
Drug: carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
Trial: NCT02107703
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered Orally
Trial: NCT02107703
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IM
Trial: NCT00790270
Drug: Cyclobenzaprine
RxNorm normalized name: Cyclobenzaprine
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg orally every 8 hours as needed
Trial: NCT00282308
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab was supplied in single-use vials.
Trial: NCT01761565
Drug: Single dose of SUF NT 15 mcg
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00282308
Drug: Methylprednisone
RxNorm normalized name: Methylprednisone
DrugBank: Methylprednisone (DB12952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
Trial: NCT01761565
Drug: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01584440
Drug: AVP-923-20
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
Trial: NCT01584440
Drug: AVP-923-30
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
Trial: NCT04056650
Drug: L-theanine
RxNorm normalized name: L-Theanine
DrugBank: Theanine (DB12444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 250 mg
Trial: NCT04065737
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308
Trial: NCT00257270
Drug: gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00337675
Drug: montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
Trial: NCT00816166
Drug: Aspirin and Clopidogrel (Medical therapy)
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
Trial: NCT00337675
Drug: montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
Trial: NCT02036970
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01871740
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Trial: NCT02350478
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
Trial: NCT01576809
Drug: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
Trial: NCT00942526
Drug: Mycostatin oral suspension
RxNorm normalized name: nystatin Oral Suspension [Mycostatin]
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
Trial: NCT02122003
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg bid
Trial: NCT01994369
Drug: EC17
RxNorm normalized name: EC17 (Folate-FITC)
DrugBank: EC-17 (DB12559)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00462397
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00462397
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00462397
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00104858
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00104858
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00104858
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00846963
Drug: Ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (\>33mmol/L) to the resolution of cholestasis (conjugated bilirubin \<34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given.
Trial: NCT03236662
Drug: (-)-Epicatechin
RxNorm normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00892736
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00218218
Drug: Transdermal Nicotine Patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 42 mg transdermal nicotine
Trial: NCT00218218
Drug: 21 mg transdermal nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00771953
Drug: apricoxib
RxNorm normalized name: Apricoxib
DrugBank: Apricoxib (DB12378)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
Trial: NCT00771953
Drug: Docetaxel or Pemetrexed
RxNorm normalized name: Docetaxel
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
Trial: NCT00578292
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6
Trial: NCT00578292
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2 Day -5 through Day -2
Trial: NCT00578292
Drug: MESNA
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg x 5 Days -5 through -2
Trial: NCT00006117
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006117
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00947193
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral powder
Trial: NCT00921518
Drug: 0.9% Sodium Chloride (Placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
Trial: NCT00921518
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
Trial: NCT00232726
Drug: CP-4055 (ELACYT)
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01302249
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: q.d.
Trial: NCT01302249
Drug: Timolol maleate ophthalmic solution 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00272532
Drug: Thiocolchicoside
RxNorm normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03196349
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
Trial: NCT03196349
Drug: Apixaban 2.5 MG
RxNorm normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Will be randomized to receive open label apixaban of 2.5 mg twice daily
Trial: NCT03196349
Drug: Rivaroxaban 10 MG
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be randomized to receive open label rivaroxaban of 10mg daily
Trial: NCT03920319
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion 150 mg sustained release
Trial: NCT02592096
Drug: 0.1% Pazufloxacin Mesilate Ear Drops
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592096
Drug: 0.3% Pazufloxacin Mesilate Ear Drops
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592096
Drug: 0.5% Pazufloxacin Mesilate Ear Drops
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592096
Drug: Pazufloxacin mesilate injection
RxNorm normalized name: pradofloxacin Injectable Product
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00735267
Drug: PD 0332334
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
Trial: NCT00006205
Drug: ondansetron + cognitive behavioral therapy
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron (4 mcg/kg b.i.d)
Trial: NCT00006205
Drug: topiramate + cognitive behavioral therapy
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topiramate (up to 300 mg/day)